PTGX
Protagonist Therapeutics, Inc Health Care Pharmaceutical Preparations Russell 3000
$144.85Close
$9.1BMarket cap
$75.95 – $158.6252-week range
Nov 5, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 92 · stronger than 92% of stocks over 12 months
Cautions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
9%
1wk
up 4.6%
price change
1mo
up 2.8%
price change
12-month return
up 86%
market up 11% ·
its own up 78%
F-score
—
— Not assessed
Altman Z
100.95
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
14.7×
price / book
Earnings yield
down 1.8%
EBIT / enterprise value
Cheaper than
18%
of the market · expensive
Revenue growth
down 89%
year on year
EPS growth
—
latest quarter
Sales growth
up 3749%
latest quarter
ROE
down 20%
return on equity
Free cash margin
up 122%
$56.1M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
3.6%
$5.25 a day · 2×ATR $134.36
RS
92 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
1.19
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 2.5% over the year, from 61m to 63m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 89.4% over the year, from $434.4M to $46.0M.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+8% vs market2 sessions after results
Financials
- Net -283%
- Free cash 122%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $28.6M | $27.4M | $26.6M | $60.0M | $434.4M | $46.0M |
| Operating income | -$64.5M | -$125.8M | -$131.4M | -$93.7M | $252.8M | -$158.1M |
| Net income | -$66.2M | -$125.6M | -$127.4M | -$79.0M | $275.2M | -$130.1M |
| Net margin | -231% | -459% | -479% | -132% | 63% | -283% |
| Earnings per share | -$1.92 | -$2.71 | -$2.60 | -$1.39 | $4.23 | -$2.05 |
| Free cash flow | -$73.0M | -$109.0M | -$108.9M | -$70.8M | $182.8M | $56.1M |
| Free cash margin | -255% | -398% | -410% | -118% | 42% | 122% |
| Cash | $117.4M | $123.7M | $125.7M | $186.7M | $97.2M | $128.4M |
| Shareholders' equity | $279.6M | $300.0M | $215.6M | $336.7M | $675.3M | $614.7M |
| Shares outstanding | 43.75m | 47.84m | 49.34m | 57.71m | 61.04m | 62.58m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 21, 2025 | Annual ↗ | Dec 31, 2024 | 52d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results · Regulation FD ↗ |
| Jun 18, 2026 | Director or officer change · Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Feb 25, 2026 | Results ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 6, 2025 | Results ↗ |
| Jun 26, 2025 | Shareholder vote ↗ |
| May 6, 2025 | Results ↗ |
| Mar 20, 2025 | Other events ↗ |
| Mar 10, 2025 | Other events ↗ |
| Mar 3, 2025 | Other events ↗ |